Covid-19 vaccine for younger kids showed strong results, says Moderna

Moderna said that its Covid-19 vaccine showed a strong immune response in younger children in a late-stage clinical trial, paving the way for submission to regulators for clearance in those aged six to under 12. 
 

An interim analysis showed a protective antibody response from children in the study, Cambridge, Massa­chusetts-based Moderna said Monday in a statement. Participants received two 50 microgram doses — half that initially given to adults — spaced 28 days apart.
 

Health officials are aiming to get immunizations to younger children before the holiday season, when travel and indoor activity can bring an increased risk of infection.